Spinal Cord Stimulation Devices Market size is set to expand considerably from 2021 to 2027, considering the increasing risks of degenerative disc diseases among older adults. In addition, the capability of the device to reduce pain and improve mobility and sleep, thereby limiting the consumption of pain medication, will stimulate the industry expansion in the coming years. Spinal cord stimulation (SCS) refers to a pain management technique involving the implantation of electrotherapeutic devices onto the spinal cord. The implanted devices introduce low levels of electrical current to the spinal cord’s dorsal portion to block the pain sensation. The spinal cord stimulation therapy is often deployed to treat neurotherapy or radiculopathy.
Increasing geriatric population, rising incidences of chronic lower back pain, and the high investment in healthcare are the key trends bolstering the market growth during the forecast timeline. According to a report from The Good Body, Americans spend over $50 billion to treat the symptoms of back pain annually, which could contribute to a surge in demand for SCS devices. Moreover, the rapid introduction of technologically advanced spinal cord stimulators will drive industry demand over the coming years. For example, in 2020, Abbott gained the approval of the U.S. FDA for its SCS system, Proclaim XR, designed with innovative recharge-free features, resulting in an extended lifespan of over ten years. However, potential complications associated with SCS implantation, including nerve damage, bleeding, and paralysis, may create a hindrance to the steady market progression during the forecast timeframe.
Complex regional pain syndrome is anticipated to emerge as a prominent application segment in the market by 2027. This is a result of the rising incidences of cardiovascular conditions, as CRPS can be triggered by conditions such as heart attack or stroke. Additionally, the development of acute compartment syndrome caused by lower leg injuries or trauma is likely to further fuel the demand for SCS devices to treat the symptoms of CRPS.
The Europe spinal cord stimulation devices market will register a significant revenue by 2027, due to the robust presence of academic centers dedicated to the research and treatment of spinal cord injuries in Germany. The increasing burden of lower back pain, especially among females, will also serve as a key driver for the regional growth over the coming years.
The competitive landscape of the market consists of companies such as Boston Scientific Corporation, St. Jude Medical (Abbott), and Medtronic, among others. These market players are focusing on innovative service launches, strategic alliances, and acquisitions to expand their footprint in the global market.
For instance, in January 2021, Abbott unveiled its digital health app, NeuroSphere myPath, designed to track and report on pain relief and general wellbeing in patients associated with spinal cord stimulation or dorsal root ganglion therapy. Also, in January 2021, Boston Scientific announced a limited release of its WaveWriter Alpha portfolio of SCS systems. This unified portfolio of 4 MRI conditional, rechargeable and non-rechargeable, Bluetooth-enabled IPGs (implantable pulse generators) was designed to provide profound paresthesia-free pain relief and uncompromised personalization.
The novel COVID-19 outbreak has presented a complex array of challenges across the healthcare industry, from the high personal risks of exposure to the difficulties in treating patients. The pandemic-induced disruptions have also been witnessed in the spinal surgical sector, particularly due to the economical strain and the concerns regarding hospital capacity. These disruptions during the pandemic may have, in turn, created roadblocks to the steady growth of the industry.
However, increased risks of virus-related complications among patients with spinal cord injury may aid industry recovery during the forecast timeline. The autonomic nervous system, which controls the immune system, can be affected by spinal cord injury, thus slowing down its ability to produce antibodies to control the virus. Therefore, the rising awareness about the potential development of severe virus infection among these patients will likely boost the adoption of SCS devices.
Market, By Product
Market, By Application
The above information is provided for the following regions and countries: